Skip to content
← Full study record

NCT00400569 · MORE INFO

Limitations, agreements, and source contact

Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma · Source last updated 2012-08-28

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
pi Sponsor Employee
true
limitations And Caveats
description
The trial was amended to exclude fibrosarcoma after only one patient was accrued while the other cohorts had completed 75% or more of their planned accrual. Only patients with liposarcoma, leiomyosarcoma, or MFH were enrolled after this amendment.
point Of Contact
email
alberto.chiappori@moffitt.org
organization
H. Lee Moffitt Cancer Center and Research Institute
phone
813-745-2158
title
Alberto Chiappori, M.D.
Complete source fields
certain Agreement
pi Sponsor Employee
true
limitations And Caveats
description
The trial was amended to exclude fibrosarcoma after only one patient was accrued while the other cohorts had completed 75% or more of their planned accrual. Only patients with liposarcoma, leiomyosarcoma, or MFH were enrolled after this amendment.
point Of Contact
email
alberto.chiappori@moffitt.org
organization
H. Lee Moffitt Cancer Center and Research Institute
phone
813-745-2158
title
Alberto Chiappori, M.D.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice